Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories informed the exchanges that its promoter, Essix Biosciences Limited, acquired 11,00,000 equity shares (face value Rs. 10 each) on August 1, 2025. The shares were obtained by converting fully convertible warrants into equity shares on a preferential basis. This acquisition represents 1.50% of the post-allotment paid-up equity share capital of the company. The disclosure was made under SEBI's Insider Trading Regulations, with Himanshu Jain signing on behalf of Essix Biosciences as a director.
This is a positive signal of promoter confidence, as the promoter entity is increasing its stake by converting warrants into equity. A 1.50% increase in promoter holding through warrant conversion suggests the promoter is willing to commit fresh capital, which is generally viewed favorably by retail investors.